Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Reports Q1 Revenue Decline as R&D Spending Surges and Profit Nearly Doubles

NEW YORK, April 26 (GenomeWeb News) - Serologicals today reported that first-quarter revenues slipped 2.8 percent as R&D spending jumped 11 percent and profits nearly doubled.


Total receipts for the three months ended April 2 fell to $55 million from $56.6 million in the year-ago period.


R&D spending increased to $5 million from $4.5 million.


Profits swell to $2.8 million, or $.08 per basic share, from $1.9 million, or $.06 per basic share year over year.


Serologicals said it had around $43 million in cash and equivalents as of April 2.


As GenomeWeb News reported yesterday, the company said it will be acquired by Millipore for $1.4 billion in cash.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.